secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001724521-23-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences Q3 net loss $71M; cash $950M; domvanalimab and AB521 updates
------------------------------------------------------------------------------

- Net loss of $71M in Q3 2023 vs $65M in Q3 2022; R&D expenses rose to $82M from $77M.
- Cash, cash equivalents and marketable securities $950M as of Sept 30, 2023, down from $1.1B at Dec 31, 2022; cash runway into 2026.
- Revenue $32M in Q3 2023, primarily from Gilead collaboration, vs $33M in Q3 2022.
- EDGE-Gastric Phase 2: domvanalimab + zimberelimab + chemo showed 80% ORR in PD-L1-high tumors; maturity PFS data expected H2 2024.
- AB521 Phase 1/1b: PK/PD consistent with healthy volunteers; no DLTs; ccRCC dose-expansion near completion; efficacy data later in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452123000018/0001724521-23-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452123000018/rcus-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001724521-23-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer